PET/CT in the staging of the non-small-cell lung cancer

Fangfang Chao, Hong Zhang, Fangfang Chao, Hong Zhang

Abstract

Lung cancer is a common disease and the leading cause of cancer-related death in many countries. Precise staging of patients with non-small-cell lung cancer plays an important role in determining treatment strategy and prognosis. Positron emission tomography/computed tomography (PET/CT), combining anatomic information of CT and metabolic information of PET, is emerging as a potential diagnosis and staging test in patients with non-small-cell lung cancer (NSCLC). The purpose of this paper is to discuss the value of integrated PET/CT in the staging of the non-small-cell lung cancer and its health economics.

References

    1. Morgensztern D, Goodgame B, Baggstrom MQ, Gao F, Govindan R. The effect of FDG-PET on the stage distribution of non-small cell lung cancer. Journal of Thoracic Oncology. 2008;3(2):135–139.
    1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA: A Cancer Journal for Clinicians. 2008;58(2):71–96.
    1. Steinert HC. PET and PET-CT of lung cancer. Methods in Molecular Biology. 2011;727:33–51.
    1. De Wever W, Coolen J, Verschakelen JA. Integrated PET/CT and cancer imaging. JBR-BTR. 2009;92(1):13–19.
    1. Low SY, Eng P, Keng GHW, Ng DCE. Positron emission tomography with CT in the evaluation of non-small cell lung cancer in populations with a high prevalence of tuberculosis. Respirology. 2006;11(1):84–89.
    1. McQuade P, Rowland DJ, Lewis JS, Welch MJ. Positron-emitting isotopes produced on biomedical cyclotrons. Current Medicinal Chemistry. 2005;12(7):807–818.
    1. Vogel WV, Oyen WJ, Barentsz JO, Kaanders JH, Corstens FH. PET/CT: panacea, redundancy, or something in between? Journal of Nuclear Medicine. 2004;45(supplement 1):15S–24S.
    1. Yau YY, Chan WS, Tam YM, et al. Application of intravenous contrast in PET/CT: does it really introduce significant attenuation correction error? Journal of Nuclear Medicine. 2005;46(2):283–291.
    1. Kligerman S, Digumarthy S. Staging of non-small cell lung cancer using integrated PET/CT. American Journal of Roentgenology. 2009;193(5):1203–1211.
    1. Tsim S, O’Dowd CA, Milroy R, Davidson S. Staging of non-small cell lung cancer (NSCLC): a review. Respiratory Medicine. 2010;104(12):1767–1774.
    1. Rami-Porta R, Crowley JJ, Goldstraw P. The revised TNM staging system for lung cancer. Annals of Thoracic and Cardiovascular Surgery. 2009;15(1):4–9.
    1. Carr LL, Finigan JH, Kern JA. Evaluation and treatment of patients with non-small cell lung cancer. Medical Clinics of North America. 2011;95(6):1041–1054.
    1. Ettinger DS, Akerley W, Bepler G, et al. Non-small cell lung cancer: clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2010;8(7):740–801.
    1. Grutters JPC, Kessels AGH, Pijls-Johannesma M, De Ruysscher D, Joore MA, Lambin P. Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis. Radiotherapy and Oncology. 2010;95(1):32–40.
    1. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303(11):1070–1076.
    1. Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. The New England Journal of Medicine. 2003;348(25):2500–2507.
    1. Fischer BM, Mortensen J. The future in diagnosis and staging of lung cancer: positron emission tomography. Respiration. 2006;73(3):267–276.
    1. Wever W, Ceyssens S, Mortelmans L, et al. Additional value of PET-CT in the staging of lung cancer: comparison with CT alone, PET alone and visual correlation of PET and CT. European Radiology. 2007;17(1):23–32.
    1. Webb WR, Gatsonis C, Zerhouni EA, et al. CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group. Radiology. 1991;178(3):705–713.
    1. Shim SS, Lee KS, Kim BT, et al. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology. 2005;236(3):1011–1019.
    1. Pauls S, Buck AK, Hohl K, et al. Improved non-invasive T-Staging in non-small cell lung cancer by integrated 18F-FDG PET/CT. NuklearMedizin. 2007;46(1):9–14.
    1. Verschakelen JA, De Wever W, Bogaert J. Role of computed tomography in lung cancer staging. Current Opinion in Pulmonary Medicine. 2004;10(4):248–255.
    1. Kerr KM, Lamb D, Wathen CG, Walker WS, Douglas NJ. Pathological assessment of mediastinal lymph nodes in lung cancer: implications for non-invasive mediastinal staging. Thorax. 1992;47(5):337–341.
    1. Gupta NC, Tamim WJ, Graeber GG, Bishop HA, Hobbs GR. Mediastinal lymph node sampling following positron emission tomography with fluorodeoxyglucose imaging in lung cancer staging. Chest. 2001;120(2):521–527.
    1. Darling GE, Maziak DE, Inculet RI, et al. Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial. Journal of Thoracic Oncology. 2011;6(8):1367–1372.
    1. Jeon TY, Lee KS, Yi CA, et al. Incremental value of PET/CT over CT for mediastinal nodal staging of non-small cell lung cancer: comparison between patients with and without idiopathic pulmonary fibrosis. American Journal of Roentgenology. 2010;195(2):370–376.
    1. Billé A, Pelosi E, Skanjeti A, et al. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography. European Journal of Cardio-Thoracic Surgery. 2009;36(3):440–445.
    1. Liu B-J, Dong J-C, Xu C-Q, et al. Accuracy of 18F-FDG PET/CT for lymph node staging in non-small-cell lung cancers. Chinese Medical Journal. 2009;122(15):1749–1754.
    1. Yang WF, Tan GZ, Fu Z, Yu JM. [Evaluation of the diagnostic value of (18)F-FDG PET-CT and enhanced CT for staging of lymph node metastasis in non-small cell lung cancer] Chinese Journal of Oncology. 2009;31(12):925–928.
    1. Tournoy KG, Maddens S, Gosselin R, Van Maele G, Van Meerbeeck JP, Kelles A. Integrated FDG-PET/CT does not make invasive staging of the intrathoracic lymph nodes in non-small cell lung cancer redundant: a prospective study. Thorax. 2007;62(8):696–701.
    1. Yi CA, Lee KS, Kim BT, et al. Efficacy of helical dynamic CT versus integrated PET/CT for detection of mediastinal nodal metastasis in non-small cell lung cancer. American Journal of Roentgenology. 2007;188(2):318–325.
    1. Perigaud C, Bridji B, Roussel JC, et al. Prospective preoperative mediastinal lymph node staging by integrated positron emission tomography-computerised tomography in patients with non-small-cell lung cancer. European Journal of Cardio-Thoracic Surgery. 2009;36(4):731–736.
    1. Metin M, Citak N, Sayar A, et al. The role of extended cervical mediastinoscopy in staging of non-small cell lung cancer of the left lung and a comparison with integrated positron emission tomography and computed tomography: does integrated positron emission tomography and computed tomography reduce the need for invasive procedures? Journal of Thoracic Oncology. 2011;6(10):1713–1719.
    1. Quint LE, Tummala S, Brisson LJ, et al. Distribution of distant metastases from newly diagnosed non-small cell lung cancer. Annals of Thoracic Surgery. 1996;62(1):246–250.
    1. Truong MT, Viswanathan C, Erasmus JJ. Positron emission tomography/computed tomography in lung cancer staging, prognosis, and assessment of therapeutic response. Journal of Thoracic Imaging. 2011;26(2):132–146.
    1. Taira AV, Herfkens RJ, Gambhir SS, Quon A. Detection of bone metastases: assessment of integrated FDG PET/CT imaging. Radiology. 2007;243(1):204–211.
    1. Heinz-Peer G, Hönigschnabl S, Schneider B, Niederle B, Kaserer K, Lechner G. Characterization of adrenal masses using MR imaging with histopathologic correlation. American Journal of Roentgenology. 1999;173(1):15–22.
    1. Jana S, Zhang T, Milstein DM, Isasi CR, Blaufox MD. FDG-PET and CT characterization of adrenal lesions in cancer patients. European Journal of Nuclear Medicine and Molecular Imaging. 2006;33(1):29–35.
    1. Yon MS, Kyung SL, Kim BT, et al. 18F-FDG PET versus 18F-FDG PET/CT for adrenal gland lesion characterization: a comparison of diagnostic efficacy in lung cancer patients. Korean Journal of Radiology. 2008;9(1):19–28.
    1. Ansquer C, Scigliano S, Mirallié E, et al. 18F-FDG PET/CT in the characterization and surgical decision concerning adrenal masses: a prospective multicentre evaluation. European Journal of Nuclear Medicine and Molecular Imaging. 2010;37(9):1669–1678.
    1. Yun M, Kim W, Alnafisi N, Lacorte L, Jang S, Alavi A. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. Journal of Nuclear Medicine. 2001;42(12):1795–1799.
    1. Perri M, Erba P, Volterrani D, et al. Adrenal masses in patients with cancer: PET/CT characterization with combined CT histogram and standardized uptake value PET analysis. American Journal of Roentgenology. 2011;197(1):209–216.
    1. Chong S, Kyung SL, Ha YK, et al. Integrated PET-CT for the characterization of adrenal gland lesions in cancer patients: diagnostic efficacy and interpretation pitfalls. Radiographics. 2006;26(6):1811–1824.
    1. Goldstraw P, Crowley J, Chansky K, et al. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. Journal of Thoracic Oncology. 2007;2(8):706–714.
    1. Salskov A, Tammisetti VS, Grierson J, Vesselle H. FLT: measuring Tumor Cell Proliferation In Vivo With Positron Emission Tomography and 3′-Deoxy-3′-[18F]Fluorothymidine. Seminars in Nuclear Medicine. 2007;37(6):429–439.
    1. Fischer B, Lassen U, Mortensen J, et al. Preoperative staging of lung cancer with combined PET-CT. The New England Journal of Medicine. 2009;361(1):32–39.
    1. van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. The Lancet. 2002;359(9315):1388–1392.
    1. Viney RC, Boyer MJ, King MT, et al. Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer. Journal of Clinical Oncology. 2004;22(12):2357–2362.
    1. Fontaine E, McShane J, Carr M, et al. Does positron emission tomography scanning improve survival in patients undergoing potentially curative lung resections for non-small-cell lung cancer? European Journal of Cardio-Thoracic Surgery. 2011;40(3):642–646.
    1. Buck AK, Herrmann K, Stargardt T, Dechow T, Krause BJ, Schreyögg J. Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches. Journal of Nuclear Medicine Technology. 2010;38(1):6–17.
    1. Allen TL, Kendi ATK, Mitiek MO, Maddaus MA. Combined contrast-enhanced computed tomography and 18-fluoro-2-deoxy-D-glucose-positron emission tomography in the diagnosis and staging of non-small cell lung cancer. Seminars in Thoracic and Cardiovascular Surgery. 2011;23(1):43–50.
    1. Devaraj A, Cook GJR, Hansell DM. PET/CT in non-small cell lung cancer staging-promises and problems. Clinical Radiology. 2007;62(2):97–108.
    1. Sloka JS, Hollett PD, Mathews M. Cost-effectiveness of positron emission tomography for non-small cell lung carcinoma in Canada. Medical Science Monitor. 2004;10(5):MT73–MT80.
    1. Buck AK, Herrmann K, Schreyögg J. PET/CT for staging lung cancer: costly or cost-saving? European Journal of Nuclear Medicine and Molecular Imaging. 2011;38(5):799–801.
    1. Schreyögg J, Weller J, Stargardt T, et al. Cost-effectiveness of hybrid PET/CT for staging of non-small cell lung cancer. Journal of Nuclear Medicine. 2010;51(11):1668–1675.
    1. Søgaard R, Fischer BMB, Mortensen J, Højgaard L, Lassen U. Preoperative staging of lung cancer with PET/CT: cost-effectiveness evaluation alongside a randomized controlled trial. European Journal of Nuclear Medicine and Molecular Imaging. 2011;38(5):802–809.
    1. Gilman MD, Fischman AJ, Krishnasetty V, Halpern EF, Aquino SL. Optimal CT breathing protocol for combined thoracic PET/CT. American Journal of Roentgenology. 2006;187(5):1357–1360.
    1. Cohade C, Osman M, Marshall LT, Wahl RL. PET-CT: accuracy of PET and CT spatial registration of lung lesions. European Journal of Nuclear Medicine and Molecular Imaging. 2003;30(5):721–726.
    1. Okada M, Shimono T, Komeya Y, et al. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions. Annals of Nuclear Medicine. 2009;23(4):349–354.
    1. Hany TF, Heuberger J, von Schulthess GK. Iatrogenic FDG foci in the lungs: a pitfall of PET image interpretation. European Radiology. 2003;13(9):2122–2127.
    1. Kim S-J, Kim Y-K, Kim IJ, Kim YD, Lee MK. Limited predictive value of dual-time-point F-18 FDG PET/CT for evaluation of pathologic N1 status in NSCLC patients. Clinical Nuclear Medicine. 2011;36(6):434–439.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj